Outlook Therapeutics Re-Submitted a BLA to the US FDA for ONS-5010 to Treat Wet Age-Related Macular Degeneration
Shots:
- The re-submission is based on 3 clinical trials, (NORSE ONE/TWO/THREE) evaluating ONS-5010 vs Lucentis in patients (n=61/228/197) with wet AMD across 9 sites in Australia & 39 in the US along with a P-I clinical trial evaluating the PK of ONS-5010 for the same indication
- The results from the (NORSE ONE) trial showed consistent data with the historical data of bevacizumab & the P-III (NORSE TWO) trial showed 41.7% gained ~15 letters of vision as 1EPs, 56.5% gained ≥10 letters as 2EPs & 68.5% gained ≤5 letters
- The company also plans to file sBLA for the approval of providing ONS-5010 in a pre-filled syringe, based on the (NORSE SEVEN) trial evaluating the safety of ONS-5010 in a vial vs pre-filled syringe in 120 patients for 3mos.
Ref: Globe Newswire | Image: Outlook Therapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
